Page last updated: 2024-09-04

moxifloxacin and Tuberculosis, Drug-Resistant

moxifloxacin has been researched along with Tuberculosis, Drug-Resistant in 116 studies

Research

Studies (116)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (5.17)	29.6817
2010's	76 (65.52)	24.3611
2020's	34 (29.31)	2.80

Authors

Authors	Studies
Chen, S; Ding, CZ; Franzblau, SG; Guo, F; Huang, Z; Li, L; Li, Y; Luo, W; Shen, L; Tang, D; Wang, B; Xu, D; Yang, M; Zhu, Y	1
Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y	1
Blackman, A; Cáceres, T; Cachay, R; Gotuzzo, E; Maruri, F; Meza, E; Schwalb, A; Sterling, TR	1
Chen, X; Fu, L; Gao, T; Huo, F; Li, Q; Lu, Y; Pang, Y; Wang, B; Zhang, X	1
Guo, Y; Liu, H; Sha, W; Shen, H; Shen, X; Tan, G; Wu, X; Wu, Z; Yang, J; Yu, F	1
Koesoemoprodjo, W; Kusmiati, T; Luthfah, N; Mertaniasih, NM; Putranto, JNE; Sari, AP; Soedarsono, S; Suprapti, B	1
Borana, H; Deokar, K; Desai, G; Purohit, G; Yogi, S	1
Gao, J; Gao, M; Li, L; Liu, F; Liu, Y; Pang, Y; Shu, W; Sun, Y; Xie, L; Zhang, L	1
Al-Zubaidi, A; Cheung, CY; Cook, GM; Dawes, SS; Lott, JS; Mizrahi, V; Taiaroa, G	1
Drlica, K; Singh, A; Zhao, X	1
Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM	1
Berry, C; Dodd, M; du Cros, P; Fielding, K; Kazounis, E; Liverko, I; McHugh, TD; Moodliar, R; Moore, DAJ; Motta, I; Ngubane, N; Nyang'wa, BT; Parpieva, N; Rassool, M; Ritmeijer, K; Solodovnikova, V; Spigelman, M; Tigay, Z	1
Chirehwa, MT; Court, R; De Kock, M; de Vries, N; Denti, P; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Resendiz-Galvan, JE; Warren, R; Wiesner, L	1
Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E	1
Borish, HJ; Budak, M; Chishti, HB; Cicchese, JM; Dartois, V; Fillmore, D; Flynn, JL; Frye, LJ; Kirschner, DE; Kracinovsky, K; Lin, PL; Linderman, JJ; Maiello, P; Sakal, J; Scanga, CA; Tomko, J; White, AG	1
Chopra, KK; Dwivedi, KK; Hanif, M; Khanna, A; Sidiq, Z; Vashishat, BK	1
Alffenaar, JW; Aryal, S; Boorgula, GD; Dheda, K; Gumbo, T; Malinga, L; Raj, P; Shankar, P; Singh, S; Srivastava, S; Thomas, TA	1
Berge, I; Bogdanova, I; Freimane, L; Norvaiša, I; Ozere, I; Ranka, R; Sadovska, D; Vaivode, A; Vīksna, A	1
Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S	1
Das, SC; Eedara, BB; Momin, MAM; Rangnekar, B; Sinha, S	1
Aljayyoussi, G; Ardrey, A; Biagini, GA; Donnellan, S; Martinez-Rodriguez, C; Moyo, E; Ward, SA	1
Aung, KJM; Decroo, T; Kuaban, C; Noeske, J; Piubello, A; Rieder, HL; Van Deun, A	1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E	1
Akkerman, OW; Alffenaar, JC; Bolhuis, MS; Ghimire, S; Jongedijk, EM; Touw, DJ; van den Elsen, SHJ; van der Werf, TS; Wessels, M	1
Chen, J; Chen, X; He, G; Li, Y; Zhang, W	1
Caminero, JA; Caylà, JA; García-García, JM; García-Pérez, FJ; Palacios, JJ; Ruiz-Manzano, J	1
Guan, Y; Liu, Y	1
Campbell, JR; Chan, ED; Gegia, M; Kwak, N; Lange, C; Lee, M; Menzies, D; Milanov, V; Winters, N; Yim, JJ	1
Affolabi, D; de Jong, BC; Decroo, T; Dusabe, T; Habimana, YM; Migambi, P; Mulders, W; Ngabonziza, JCS; Niyigena, EB; Rigouts, L; Supply, P; Ushizimpumu, B; Van Deun, A	1
Jain, AK; Sharma, P	1
Akhtar, SM; Kaur, H; Mittal, GK; Reddy, VASK	1
Alffenaar, JW; Bruchfeld, J; Davies Forsman, L; Eliasson, E; Hoffner, S; Hong, C; Hu, Y; Ke, R; Kuhlin, J; Niward, K; Paues, J; Schön, T; Simonsson, USH; Werngren, J; Xu, B; Zheng, R; Zheng, X	1
Qiujing, F; Weiwei, W	1
Chen, J; Chen, X; He, G; Lin, S; Sun, F; Wang, S; Zhang, W	1
Du, J; Gao, J; Li, L; Liu, Y; Pang, Y; Shu, W; Wang, Y; Xue, Z	1
Ahmad, N; Atif, M; Ghafoor, A; Iqbal, Q; Khan, S; Latif, A; Saleem, F; Wahid, A	1
Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Akkerman, OW; Alffenaar, JC; Bolhuis, MS; de Lange, WC; Kerstjens, HA; Oswald, LM; van der Werf, TS; Van Kampenhout, E	1
Bao, L; Luo, T; Mi, Y; Peng, X; Sun, C; Wang, C; Yang, G; Yuan, J; Zhang, C	1
Duarte, R; Macedo, R; Mendes-Bastos, P	1
Jo, KW; Nam, GB; Shim, TS; Yoon, HY	1
Mamatha, HG; Shanthi, V	1
Andres, S; Beckert, P; Heyckendorf, J; Hillemann, D; Kohl, TA; Köser, CU; Lange, C; Merker, M; Moradigaravand, D; Niemann, S; Olaru, ID; Parkhill, J; Peacock, SJ; Schleusener, V; Schön, T; Sturegård, E	1
Bablishvili, N; Bernheim, A; Blumberg, HM; Derendorf, H; Gogishvili, S; Guarner, J; Heinrichs, MT; Kempker, RR; Little, BP; Nikolaishvili, K; Peloquin, CA; Sabulua, I; Tukvadze, N; Vashakidze, S	1
Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T	1
Akkerman, OW; Bathoorn, E; de Lange, WCM; Lokate, M; Louka, C; Pournaras, S; Ravensbergen, SJ; Stienstra, Y; van der Werf, TS	1
Aktoğu Özkan, S; Biçmen, C; Çavuşoğlu, C; Eraç, B; Ermertcan, Ş; Hoşgör Limoncu, M; Yılmaz, FF	1
Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M	1
Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM	1
Alvarez-Cabrera, N; Blanc, L; Dartois, V; Dias-Freedman, I; Dietzold, J; Ho Liang, HP; Kaya, F; Kirschner, D; Linderman, J; Mina, M; O'Brien, P; Pienaar, E; Prideaux, B; Salgame, P; Sarathy, J; Savic, RM; Zimmerman, M	1
Chiang, CY; Conradie, F; Dalai, D; Dat, PT; Lan, N; Master, I; Mebrahtu, T; Meredith, SK; Meressa, D; Moodliar, R; Ngubane, N; Nunn, AJ; Phillips, PPJ; Rusen, ID; Sanders, K; Squire, SB; Torrea, G; Tsogt, B; van Deun, A	1
Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V	1
Khalid, UK; Kumar Verma, A; Mathuria, KK; Munjal, S; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Vohra, V	1
Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA	1
Jiang, Y; Li, G; Li, M; Liu, H; Liu, Z; Wan, K; Wang, R; Xu, D; Xu, Z; Zhao, LL; Zhao, X	1
Bethunaickan, R; Chandramohan, Y; Padmanaban, V; Ranganathan, UD; Swaminathan, S; Tripathy, S	1
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH	1
Schaberg, T	1
Jiang, RH; Li, L; Xu, HB	1
Chan Kim, K; Choi, JC; Choi, SB; Choi, WI; Heo, EY; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Ki, YW; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, J; Lee, JH; Lee, SH; Lee, YS; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH	1
Alcántara, F; Atwood, SS; Becerra, MC; Bonilla, CA; Mitnick, CD; Seung, KJ	1
Schluger, NW	1
Charalambous, S; Chigutsa, E; Denti, P; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Mungofa, S; Simonsson, US; Sirgel, FA; Wiesner, L; Zvada, SP	1
Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S	1
Jo, KW; Kim, DS; Kim, WS; Lee, SD; Shim, TS	1
Ajbani, K; Catanzaro, A; Caviedes, L; Coronel, J; Crudu, V; Desmond, E; Eisenach, K; Ganiats, TG; Garfein, RS; Groessl, EJ; Jackson, RL; Klages, S; Moore, D; Rodrigues, C; Rodwell, TC; Romancenco, E; Trollip, AP; Victor, T; Vineet, VP	1
Jeong, BH; Koh, WJ; Kwon, YS	1
Blyth, CC; Colby, S; Fagan, JM; Francis, JR; Waring, J	1
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA	1
Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A	1
Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Thee, S; Wiesner, L	1
Babu, S; Chhajed, P; Dalal, A; Das, M; Desai, R; Isaakidis, P; Jayalakshmi, TK; Pawaskar, A; Prabhudesai, P; Rajan, S; Reddy, D; Rodrigues, C; Saranchuk, P	1
Farhat, MR; Franke, MF; Jacobson, KR; Kaur, D; Mitnick, CD; Murray, M; Sloutsky, A	1
Ahuja, SD; Proops, DC; Trieu, L	1
Migliori, GB; Sotgiu, G	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Donald, PR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S	1
Ghim, JR; Kim, DH; Kim, JH; Lee, HK; Lee, SH; Lee, YM; Seo, KA; Shin, C; Shin, JG	1
Gupta, P; Gupta, UD; Khuller, GK; Kumar, V; Tanushree, P; Vemuri, N	1
Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY	1
Bae, DW; Cho, SN; Dartois, V; Desta, KT; Eum, SY; Lee, SJ; Shin, SC	1
Chiang, CJ; Chien, JY; Chien, ST; Chiu, WY; Hsueh, PR; Yu, CJ	1
Choi, JC; Choi, SB; Choi, WI; Heo, E; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Kim, KC; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, HK; Lee, JH; Lee, SH; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH	1
Gillespie, SH	1
Corelli, F; Frosini, M; Saponara, S; Sgaragli, G	1
Chien, JY; Chien, ST; Chiu, WY; Hsueh, PR; Yu, CJ	1
Lu, JM; Sha, W; Xiao, HP; Yang, H; Zhang, LL; Zhang, Q	1
Chiang, CY; Rieder, HL; Van Deun, A	1
Blackmore, T; McNaughton, A; McNaughton, H	1
Karak, A; Mukhopadhay, S; Paul, R; Santra, G	1
Deshpande, D; Gumbo, T; Nuermberger, E; Pasipanodya, JG; Srivastava, S; Swaminathan, S	1
Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A	1
Fang, X; Li, Q; Ou, X; Pang, Y; Song, Y; Wang, S; Wang, Y; Xia, H; Zhang, Z; Zhao, B; Zhao, Y; Zheng, Y; Zhou, Y	1
Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ	1
Cooke, G; Fortunak, J; Gotham, D; Hill, A; Khoo, S; Nytko, FE; Pozniak, A	1
Mendel, C; Murray, S; Spigelman, M	1
Sterling, TR	1
Rieder, HL	1
Bergmann, JF; Delcey, V; Raskine, L; Sanson-Le-Pors, MJ; Sellier, P	1
Mohapatra, PR	1
Gumbo, T	1
Chan, RC; Chang, KC; Yew, WW	1
Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N	1
Bertaina, C; Bignamini, E; Cordola, G; Esposito, I; Mignone, F; Milano, R; Pinon, M; Scolfaro, C; Tovo, PA	1
Butcher, PD; Coleman, D; Cosgrove, CA; Delgado, R; Feasey, NA; Harrison, T; Mitchison, DA; Pond, M; Solomon, AW	1
Aarnoutse, RE; Alffenaar, JW; Kosterink, JG; Pranger, AD; Uges, DR; van Altena, R; van der Werf, TS	1
Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK	1
Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, J; Lee, JH; Lee, SM; Yang, SC; Yim, JJ; Yoo, CG; Yoon, HI	1
Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE	1
Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; Kremer, K; ten Kate, MT; van Soolingen, D; Verbrugh, HA	1
Bourdon, O; Chauny, JV; De Lauzanne, A; Doit, C; Géréral, T; Lorrot, M; Prot-Labarthe, S	1
Chatzika, K; Kioumis, I; Manika, K; Zarogoulidis, K	1
Brunori, L; Fattorini, L; Giannoni, F; Iona, E; Mattei, M; Orefici, G; Recchia, S; Tan, D	1
Dashieva, DG; Elistratova, NA; Mikhaĭlova, LP; Mozhokina, GN; Sokolova, GB	1
Codecasa, LR; Ferrara, G; Ferrarese, M; Lacchini, C; Migliori, GB; Morandi, MA; Penati, V; Vaccarino, P	1

Reviews

13 review(s) available for moxifloxacin and Tuberculosis, Drug-Resistant

Article	Year
Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement. Frontiers in cellular and infection microbiology, 2022, Volume: 12 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Cysteine; Disinfectants; DNA Gyrase; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; NAD; Reactive Oxygen Species; Tuberculosis, Multidrug-Resistant	2022
[Treatment of tuberculosis: what is new?] Innere Medizin (Heidelberg, Germany), 2023, Volume: 64, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults. Medicine, 2020, Jun-19, Volume: 99, Issue:25 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2020
Changes in treatment for multidrug-resistant tuberculosis according to national income. The European respiratory journal, 2020, Volume: 56, Issue:5 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant	2020
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet (London, England), 2018, 09-08, Volume: 392, Issue:10150 Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2018
[Tuberculosis: new treatment options and updated recommendations]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:14 Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2013
Tuberculosis: clinical trials and new drug regimens. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2014
Managing multidrug-resistant tuberculosis in children: review of recent developments. Current opinion in infectious diseases, 2014, Volume: 27, Issue:3 Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2014
Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinburgh, Scotland), 2015, Volume: 95, Issue:3 Topics: Age Factors; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2015
The role of moxifloxacin in tuberculosis therapy. European respiratory review : an official journal of the European Respiratory Society, 2016, Volume: 25, Issue:139 Topics: Animals; Antibiotics, Antitubercular; Drug Repositioning; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Lung; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy. Current medicinal chemistry, 2016, Volume: 23, Issue:21 Topics: Antitubercular Agents; Bacterial Proteins; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Mycobacterium tuberculosis; Prospective Studies; Tuberculosis; Tuberculosis, Multidrug-Resistant	2016
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:8 Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant	2010

Trials

9 trial(s) available for moxifloxacin and Tuberculosis, Drug-Resistant

Article	Year
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2022, 12-22, Volume: 387, Issue:25 Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2022
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda	2019
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. American journal of respiratory and critical care medicine, 2013, Oct-01, Volume: 188, Issue:7 Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Republic of Korea; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2013
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1 Topics: Adult; Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Moxifloxacin; Ofloxacin; Tuberculosis, Multidrug-Resistant; Young Adult	2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, Sep-09, Volume: 15 Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Annals of the American Thoracic Society, 2016, Volume: 13, Issue:3 Topics: Adult; Anti-Bacterial Agents; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Republic of Korea; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2016

Other Studies

94 other study(ies) available for moxifloxacin and Tuberculosis, Drug-Resistant

Article	Year
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorganic & medicinal chemistry letters, 2022, 09-01, Volume: 71 Topics: Animals; Antitubercular Agents; Long QT Syndrome; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic & medicinal chemistry letters, 2022, 09-15, Volume: 72 Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru. BMC research notes, 2021, Nov-14, Volume: 14, Issue:1 Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Peru; Pharmaceutical Preparations; Tuberculosis; Tuberculosis, Multidrug-Resistant	2021
Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in Microbial drug resistance (Larchmont, N.Y.), 2022, Volume: 28, Issue:3 Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA Gyrase; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Tuberculosis, Multidrug-Resistant	2022
Use of Whole-Genome Sequencing to Predict Microbiology spectrum, 2022, 04-27, Volume: 10, Issue:2 Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant	2022
Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens. Acta medica Indonesiana, 2022, Volume: 54, Issue:1 Topics: Antitubercular Agents; C-Reactive Protein; Cytokines; Electrocardiography; Humans; Interleukin-6; Long QT Syndrome; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tumor Necrosis Factor-alpha	2022
Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2022, May-04, Volume: 93, Issue:1 Topics: Antitubercular Agents; Fluoroquinolones; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study. Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9 Topics: Antitubercular Agents; Clofazimine; Creatinine; Diarylquinolines; Humans; Levofloxacin; Long QT Syndrome; Moxifloxacin; Nomograms; Tuberculosis, Multidrug-Resistant	2022
RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria. Antimicrobial agents and chemotherapy, 2022, 10-18, Volume: 66, Issue:10 Topics: Anti-Bacterial Agents; Antitubercular Agents; Cell Death; Humans; Isoniazid; Moxifloxacin; Mycobacterium Infections; Mycobacterium tuberculosis; Rifampin; RNA; Streptomycin; Tuberculosis, Multidrug-Resistant	2022
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis. Scientific reports, 2022, 10-22, Volume: 12, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization	2022
Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling. Antimicrobial agents and chemotherapy, 2023, 03-16, Volume: 67, Issue:3 Topics: Adult; Alkynes; Antitubercular Agents; Female; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant	2023
Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens. PLoS computational biology, 2023, Volume: 19, Issue:6 Topics: Animals; Antitubercular Agents; Mice; Moxifloxacin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0. The Indian journal of tuberculosis, 2023, Volume: 70, Issue:3 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. International journal of antimicrobial agents, 2023, Volume: 62, Issue:6 Topics: Antitubercular Agents; beta-Lactamase Inhibitors; Humans; Isoniazid; Linezolid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant	2023
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. BMC infectious diseases, 2023, Sep-28, Volume: 23, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Latvia; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2023
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. PloS one, 2023, Volume: 18, Issue:10 Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil	2023
Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International journal of pharmaceutics, 2019, Oct-30, Volume: 570 Topics: A549 Cells; Administration, Inhalation; Aerosols; Antitubercular Agents; Cell Line; Cell Line, Tumor; Chemistry, Pharmaceutical; Diarylquinolines; Drug Compounding; Dry Powder Inhalers; Excipients; Humans; Moxifloxacin; Particle Size; Powders; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis. Antimicrobial agents and chemotherapy, 2019, 12-20, Volume: 64, Issue:1 Topics: Antitubercular Agents; Cell Line; Computer Simulation; Decision Support Techniques; Drug Development; Fluoroquinolones; Humans; Macrophages; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; THP-1 Cells; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2019, 09-01, Volume: 23, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug Administration Schedule; Female; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Niger; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult	2019
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. The European respiratory journal, 2020, Volume: 55, Issue:5 Topics: Adult; Antitubercular Agents; Drug Monitoring; Female; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Netherlands; Prospective Studies; Saliva; Tuberculosis, Multidrug-Resistant	2020
Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 96 Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genotype; Humans; Male; Middle Aged; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2020
Update of SEPAR guideline «Diagnosis and Treatment of Drug-Resistant Tuberculosis». Archivos de bronconeumologia, 2020, Volume: 56, Issue:8 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2020
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis. The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:4 Topics: Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; High-Throughput Nucleotide Sequencing; Humans; Kanamycin; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Rwanda; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant	2020
Ethionamide induced blue vision (cyanopsia): Case report. The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3 Topics: Aminosalicylic Acid; Antitubercular Agents; Color Vision Defects; Cycloserine; Ethionamide; Female; Humans; Kanamycin; Linezolid; Moxifloxacin; Tuberculosis, Multidrug-Resistant; Young Adult	2020
Moxifloxacin induced encephalopathy in disseminated tuberculosis: A case report. The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3 Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Deprescriptions; Discitis; Electroencephalography; Encephalitis; Humans; Male; Moxifloxacin; Neurotoxicity Syndromes; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tuberculosis, Spinal	2020
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. The European respiratory journal, 2021, Volume: 57, Issue:3 Topics: Antitubercular Agents; China; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pharmaceutical Preparations; Prospective Studies; Tuberculosis, Multidrug-Resistant	2021
Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:3(Special) Topics: Adult; Antibiotics, Antitubercular; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Random Allocation; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2020
Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing. mSphere, 2020, 12-23, Volume: 5, Issue:6 Topics: Amikacin; Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Retrospective Studies; Treatment Failure; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2020
Stepwise selection of mutation conferring fluroquinolone resistance: multisite MDR-TB cohort study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021, Volume: 40, Issue:8 Topics: Antitubercular Agents; Cohort Studies; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Humans; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Retrospective Studies; Selection, Genetic; Tuberculosis, Multidrug-Resistant	2021
Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review. The American journal of tropical medicine and hygiene, 2021, 03-15, Volume: 104, Issue:5 Topics: Adult; Amikacin; Antitubercular Agents; Clofazimine; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Lost to Follow-Up; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pakistan; Pyrazinamide; Retrospective Studies; Survival Analysis; Treatment Failure; Tuberculosis, Multidrug-Resistant	2021
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 04-28, Volume: 74, Issue:8 Topics: Adult; Child; Child, Preschool; Electrocardiography; Fluoroquinolones; HIV Infections; Humans; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. The European respiratory journal, 2017, Volume: 49, Issue:3 Topics: Adult; Antitubercular Agents; Female; Fluoroquinolones; Humans; Linezolid; Moxifloxacin; Mycobacterium tuberculosis; Pregnancy; Tuberculosis, Multidrug-Resistant	2017
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7 Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Fitness; Genomics; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Ofloxacin; Sequence Analysis, DNA; Tuberculosis; Tuberculosis, Multidrug-Resistant	2017
Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? The British journal of dermatology, 2017, Volume: 177, Issue:4 Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Clindamycin; Contraindications, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant	2017
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 09-01, Volume: 21, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult	2017
Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India. Journal of global antimicrobial resistance, 2018, Volume: 12 Topics: Adolescent; Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; India; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Prospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult	2018
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:2 Topics: Antitubercular Agents; Bacterial Typing Techniques; Cohort Studies; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genome, Bacterial; Genotype; Humans; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Phenotype; Rifampin; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2018
Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. The Journal of antimicrobial chemotherapy, 2018, 02-01, Volume: 73, Issue:2 Topics: Adult; Antitubercular Agents; Female; Georgia (Republic); Humans; Lung; Male; Microdialysis; Middle Aged; Moxifloxacin; Serum; Topoisomerase II Inhibitors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2018
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. Bioinformatics (Oxford, England), 2018, 05-15, Volume: 34, Issue:10 Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant	2018
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis. The American journal of tropical medicine and hygiene, 2018, Volume: 98, Issue:2 Topics: Adult; Amikacin; Carbapenem-Resistant Enterobacteriaceae; Clofazimine; Drug Monitoring; Humans; Linezolid; Male; Moxifloxacin; Netherlands; Prevalence; Prothionamide; Refugees; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Multidrug-Resistant	2018
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates. Tuberkuloz ve toraks, 2018, Volume: 66, Issue:1 Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant; Turkey	2018
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:12 Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant	2018
Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5 Topics: Animals; Antitubercular Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Rabbits; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant	2019
Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1 Topics: Adult; Cardiotoxicity; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imipenem; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Salvage Therapy; Sputum; Survival Rate; Tuberculosis, Multidrug-Resistant; Young Adult	2019
Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India. The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1 Topics: Adult; Antitubercular Agents; Cardiotoxicity; Clofazimine; Cycloserine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Ethionamide; Female; Humans; India; Linezolid; Male; Moxifloxacin; National Health Programs; Sputum; Time Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2019
Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. International journal of antimicrobial agents, 2019, Volume: 54, Issue:5 Topics: Antitubercular Agents; Capreomycin; China; Clofazimine; Drug Synergism; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Journal of global antimicrobial resistance, 2019, Volume: 19 Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis, Multidrug-Resistant; Xanthenes	2019
Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. International journal of antimicrobial agents, 2013, Volume: 42, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Aza Compounds; China; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult	2013
Salvage therapy for multidrug-resistant tuberculosis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2014, Volume: 20, Issue:5 Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Capreomycin; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Male; Moxifloxacin; Mycobacterium tuberculosis; Retrospective Studies; Rifampin; Salvage Therapy; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult	2014
Fluoroquinolones in the treatment of tuberculosis: which is best? American journal of respiratory and critical care medicine, 2013, Oct-01, Volume: 188, Issue:7 Topics: Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2013
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2 Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:1 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Registries; Republic of Korea; Retrospective Studies; Tertiary Care Centers; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2014
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:2 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Kanamycin; Microbial Sensitivity Tests; Microscopy; Moldova; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Peru; Predictive Value of Tests; Reproducibility of Results; South Africa; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
Multidrug-resistant tuberculosis in Western Australia, 1998-2012. The Medical journal of Australia, 2014, Apr-07, Volume: 200, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Child; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hospitalization; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Retrospective Studies; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Western Australia; Young Adult	2014
Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Feb-15, Volume: 60, Issue:4 Topics: Adolescent; Antibiotics, Antitubercular; Area Under Curve; Child; Drug Tolerance; Female; Fluoroquinolones; Half-Life; HIV Infections; Humans; Male; Moxifloxacin; Prospective Studies; South Africa; Tuberculosis, Multidrug-Resistant	2015
Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time. PloS one, 2015, Volume: 10, Issue:1 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ethionamide; Female; Fluoroquinolones; Humans; India; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Precision Medicine; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult	2015
Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:3 Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2015
Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA. Emerging infectious diseases, 2015, Volume: 21, Issue:3 Topics: Antibiotic Prophylaxis; Antitubercular Agents; Coinfection; Fluoroquinolones; Follow-Up Studies; HIV Infections; Humans; Moxifloxacin; Mycobacterium tuberculosis; New York City; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2015
New effective antituberculosis regimens. Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB. Yonsei medical journal, 2015, Volume: 56, Issue:4 Topics: Adult; Aged; Antitubercular Agents; Chromatography, High Pressure Liquid; Cycloserine; Fluoroquinolones; Humans; Medication Adherence; Middle Aged; Moxifloxacin; Prothionamide; Retrospective Studies; Sputum; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant; Young Adult	2015
Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model. The Indian journal of medical research, 2015, Volume: 142, Issue:3 Topics: Animals; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Econazole; Fluoroquinolones; Humans; Mice; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant	2015
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Jan-15, Volume: 1009-1010 Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Humans; Levofloxacin; Limit of Detection; Moxifloxacin; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant	2016
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4 Topics: Anti-Bacterial Agents; Asian People; Codon; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Europe; Fluoroquinolones; Gene Expression; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Taiwan; Tuberculosis, Multidrug-Resistant; United States; White People	2016
Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8 Topics: Aged; Antitubercular Agents; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Taiwan; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2016
[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2016, Volume: 39, Issue:6 Topics: Aminosalicylic Acids; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Retreatment; Rifabutin; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, Volume: 20, Issue:9 Topics: Antitubercular Agents; Bangladesh; Blood Glucose; Cameroon; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Niger; Pilot Projects; Prevalence; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2016
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand. The European respiratory journal, 2016, Volume: 48, Issue:4 Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary	2016
Gitelman-like Syndrome with Kanamycin Toxicity. The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5 Topics: Adult; Alkalosis; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Hypokalemia; Kanamycin; Moxifloxacin; Muscle Cramp; Potassium; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Nov-01, Volume: 63, Issue:suppl 3 Topics: Antitubercular Agents; Bacterial Load; beta-Lactams; Child; Computer Simulation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant	2016
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 56 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization	2017
Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:2 Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Prevalence; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2017
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of pharmaceutical and biomedical analysis, 2017, Feb-20, Volume: 135 Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2017
Estimated generic prices for novel treatments for drug-resistant tuberculosis. The Journal of antimicrobial chemotherapy, 2017, 04-01, Volume: 72, Issue:4 Topics: Algorithms; Antitubercular Agents; Commerce; Diarylquinolines; Drug Costs; Drugs, Generic; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2016
Fourth-generation fluoroquinolones in tuberculosis. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Anti-Infective Agents; Aza Compounds; Drug Administration Schedule; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
Moxifloxacin versus ethambutol in initial tuberculosis treatment. Lancet (London, England), 2009, Jun-27, Volume: 373, Issue:9682 Topics: Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Ethambutol; Fluoroquinolones; Humans; Medication Adherence; Moxifloxacin; Patient Selection; Practice Guidelines as Topic; Quinolines; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug? American journal of respiratory and critical care medicine, 2009, Oct-01, Volume: 180, Issue:7 Topics: Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics, 2010, Volume: 126, Issue:5 Topics: Acetamides; Antitubercular Agents; Aza Compounds; Child, Preschool; Emigrants and Immigrants; Female; Fluoroquinolones; Follow-Up Studies; Humans; Infant; Italy; Linezolid; Male; Microbial Sensitivity Tests; Moldova; Moxifloxacin; Oxazolidinones; Quinolines; Romania; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2010
Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:3 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2011
Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Therapeutic drug monitoring, 2011, Volume: 33, Issue:3 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Monitoring; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Treatment Failure; Tuberculosis, Multidrug-Resistant	2011
Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 10 Topics: Antitubercular Agents; Aza Compounds; Biopsy; Brain; Cerebrospinal Fluid; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Histocytochemistry; Humans; Isoniazid; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Multidrug-Resistant; Young Adult	2011
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. The Korean journal of internal medicine, 2011, Volume: 26, Issue:2 Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Ofloxacin; Quinolines; Recurrence; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2011
Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PloS one, 2012, Volume: 7, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Markov Chains; Mice; Models, Theoretical; Moxifloxacin; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Quinolines; Rifampin; Tuberculosis, Multidrug-Resistant	2012
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerging infectious diseases, 2012, Volume: 18, Issue:4 Topics: Amikacin; Antitubercular Agents; Aza Compounds; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Rifampin; Statistics, Nonparametric; Tuberculosis, Multidrug-Resistant	2012
Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases. The Pediatric infectious disease journal, 2012, Volume: 31, Issue:12 Topics: Adolescent; Antitubercular Agents; Aza Compounds; Child; Child, Preschool; Female; Fluoroquinolones; France; Hospitals, University; Humans; Infant; Levofloxacin; Male; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2012
Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring? The European respiratory journal, 2012, Volume: 40, Issue:4 Topics: Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Tuberculosis, Multidrug-Resistant	2012
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:1 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Ethionamide; Fluoroquinolones; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Tuberculosis, Multidrug-Resistant	2003
[Comparative efficiency of treatment with moxyfloxacin and lomefloxacin for generalized murine tuberculosis caused by drug-resistant Mycobacterium strains]. Problemy tuberkuleza i boleznei legkikh, 2005, Issue:2 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Liver; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Quinolones; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2005
Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respiratory medicine, 2006, Volume: 100, Issue:9 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Italy; Male; Moxifloxacin; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2006